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Abstract 
Background: Optimal delivery of regular benzathine penicillin G (BPG) injections prescribed as secondary 
prophylaxis for acute rheumatic fever (ARF) and rheumatic heart disease (RHD) is vital to preventing disease 
morbidity and cardiac sequelae in affected pediatric and young adult populations. However, poor uptake of 
secondary prophylaxis remains a significant challenge to ARF/RHD control programs.  
Objective: In order to facilitate better understanding of this challenge and thereby identify means to improve 
service delivery, this systematic literature review explored rates of adherence and factors associated with 
adherence to secondary prophylaxis for ARF and RHD worldwide. 
Methods: MEDLINE was searched for relevant primary studies published in the English language from 
1994-2014, and a search of reference lists of eligible articles was performed. The methodological quality of 
included studies was evaluated using a modified assessment tool. 
Results: Twenty studies were included in the review. There was a range of adherence to varying regimens of 
secondary prophylaxis reported globally, and a number of patient demographic, clinical, socio-cultural and 
health care service delivery factors associated with adherence to secondary prophylaxis were identified. 
Conclusion: Insights into factors associated with lower and higher adherence to secondary prophylaxis may 
be utilized to facilitate improved delivery of secondary prophylaxis for ARF and RHD. Strategies may 
include ensuring an effective active recall system, providing holistic care, involving community health 
workers and delivering ARF/RHD health education. 
 
Keywords 
Acute rheumatic fever, rheumatic heart disease, benzathine penicillin, benzathine benzylpenicillin, penicillin 
G benzathine, secondary prophylaxis, adherence, compliance 
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Introduction 
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are a cause of significant morbidity and 
cardiac mortality amongst pediatric and young adult populations in developing countries, migrants from 
these nations and minority populations in developed countries.[1] The annual worldwide incidence of ARF 
has been estimated at over 471 000,[2] with major and minor clinical manifestations including carditis, 
arthritis, chorea, erythema marginatum, subcutaneous nodules, arthralgia and fever.[3] RHD resulting from 
recurrent episodes of ARF has an estimated prevalence of at least 15.6 million people globally.[2] An 
approximate worldwide mortality of 233 000 people per annum[2] is attributed to complications of valvular 
disease including arrhythmias, heart failure, thromboembolism and infective endocarditis.[3] 
 
Secondary prophylaxis with regular intramuscular injections of benzathine penicillin G (BPG) is a key 
component of ARF and RHD control programs. This approach aims to prevent group A beta-hemolytic 
streptococci (GAS) infections and subsequent recurrent episodes of ARF.[4] The World Health Organization 
(WHO) recommends 3-4 weekly BPG continued for a duration dependent on factors including age, time 
since the last episode of ARF, risk of streptococcal infections in the area and presence of RHD.[4] According 
to WHO guidelines, secondary prophylaxis should continue for at least 5 years after the last episode of ARF 
or until the age of 18 years (whichever is longer) and for a greater length of time in cases of carditis or 
RHD.[4, 5] However, local health authorities give slightly varying recommendations for the frequency and 
duration of BPG injections.[5]  
 
Low adherence with secondary prophylaxis is one of the main challenges to effective control of ARF and 
RHD.[4] To the best of our knowledge, a systematic literature review to summarize what is known regarding 
rates of adherence and factors associated with adherence to secondary prophylaxis does not exist.  This study 
aims to systematically summarize and evaluate published rates of adherence and factors associated with 
adherence to BPG injections prescribed as secondary prophylaxis for ARF and RHD, and thereby identify 
means to improve secondary prophylaxis interventions. In contrast to other studies of adherence in chronic 
disease management, of particular interest and importance in this review is the focus of adherence amongst 
poor and underserved population groups. 
 
Methods 
Protocol and focus 
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This systematic review has been conducted using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.[6] The review focuses on studies that explored rates of adherence and 
factors associated with adherence to BPG injections recommended as secondary prophylaxis for ARF and 
RHD worldwide. 
 
Search criteria 
A search of the MEDLINE database via OvidSP was conducted on 28 June 2014. All articles written in the 
English language between January 1, 1994 and June Week 3, 2014, using the Medical Subject Headings 
(MeSH) and keywords, (“acute rheumatic fever” OR “rheumatic fever” OR “rheumatic heart disease”) AND 
(“secondary prophylaxis” OR “secondary prevention” OR “benzathine penicillin G” OR “penicillin G 
benzathine” OR “benzathine penicillin” OR “benzathine benzylpenicillin” OR “disease management” OR 
“management”) AND (“patient compliance” OR “compliance” OR “non-compliance” OR “noncompliance” 
OR “treatment refusal” OR “guideline adherence” OR “medication adherence” OR “adherence” OR “non-
adherence” OR “nonadherence” OR “alignment” OR “non-alignment” OR “nonalignment”), were retrieved. 
A single investigator (PK) screened the titles and abstracts of all retrieved citations and performed full text 
reviews of relevant studies. Reference lists of relevant studies were hand searched to identify additional 
relevant publications. 
 
Eligibility criteria 
Eligibility criteria were determined with expert input from two pediatricians. Primary studies published from 
January 1, 1994 to June Week 3, 2014, were included in the literature review if they reported rates of 
adherence to secondary prophylaxis for ARF/RHD or discussed factors associated with adherence to BPG 
injections recommended as secondary prophylaxis for ARF/RHD.  
 
Articles that were not primary studies or were irrelevant to the focus of this review were excluded. This 
included articles written about the epidemiology and clinical presentation of ARF/RHD, symptomatic 
treatment of ARF episodes, the efficacy of differing antibiotic regimens prescribed as secondary prophylaxis 
for ARF/RHD and guidelines for delivery of secondary prophylaxis for ARF/RHD, without reference to rates 
of adherence or factors associated with adherence to secondary prophylaxis for ARF/RHD. 
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Data extraction and quality assessment 
One investigator (PK) used a standardized sheet to extract data from included studies. Data extracted 
included the author, year of publication, source, location of study, study design and study population 
characteristics. Study findings addressing rates of adherence to secondary prophylaxis for ARF/RHD and 
factors associated with adherence to secondary prophylaxis for ARF/RHD were also summarized. 
 
We created a quality assessment tool to evaluate the methodological quality of included studies incorporating 
validated elements of Pluye et al.’s Mixed Methods Assessment Tool (MMAT)[7] and Wells et al.’s 
checklists for non-randomized studies in systematic reviews[8]. Our tool assessed methodological quality in 
ten domains including the incorporation of clear study objectives with suitable data collection, clarity of 
adherence definition, sample size adequacy, recruitment method, comparability of participant groups, 
outcome measure rate/response rate, use of inferential statistical analysis, inclusion of multivariate analysis, 
consideration given to the contextual relation of findings and consideration given to researchers’ influence on 
study findings (Table 1).  
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Table 1: Quality assessment tool 
Assessment criteria Yes No 
Clear research objectives 
with suitable data collection 
Research objectives clearly outlined 
and data collected addresses 
research objectives 
Research objectives not clearly 
outlined or data collected does not 
adequately address research objectives 
Definition of adherence to 
secondary prophylaxis clear 
Adherence and non-adherence or 
levels of adherence to secondary 
prophylaxis clearly defined 
Adherence, non-adherence or levels of 
adherence to secondary prophylaxis not 
clearly defined 
Sample size calculation 
reported and target sample 
size reached 
Sample size calculation performed 
and target sample size reached 
Sample size calculation not performed 
or reported, or sample size calculation 
performed and target sample size not 
reached 
Recruitment of participants 
used probability sampling 
All or a randomly selected 
proportion of all persons on a 
register included 
Neither all nor a randomly selected 
proportion of all persons on a register 
included 
Participant groups 
comparable 
Key demographic information 
comparing participant groups is 
presented and there are no obvious 
dissimilarities that may account for 
differences in outcomes, or 
dissimilarities are taken into 
account in data analysis. 
There are apparent dissimilarities 
between participant groups that may 
account for differences in outcomes 
and these dissimilarities are not taken 
into account in data analysis. 
Outcome data 
complete/Response rate 
acceptable 
Outcome data ≥80% 
complete/Response rate ≥60% 
Outcome data <80% 
complete/Response rate <60% 
Any inferential statistical 
analysis 
Inferential statistical analysis 
performed 
Inferential statistical analysis not 
performed 
Multivariate analysis of 
factors associated with 
adherence 
Multivariate analysis of factors 
associated with adherence 
performed 
Multivariate analysis of factors 
associated with adherence not 
performed 
Consideration given to 
contextual relation of 
findings (qualitative studies) 
Explanation of how study findings 
relate to the study context or 
context characteristics given 
Explanation of how study findings 
relate to the study context or context 
characteristics not given 
Consideration given to 
researchers’ influence in 
relation to findings 
(qualitative studies) 
Researchers critically explained 
how findings relate to their 
perspectives, roles and interactions 
with participants 
Researchers did not critically explain 
how findings relate to their 
perspectives, roles and interactions 
with participants 
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Results 
Search results and quality assessment 
Electronic searching retrieved 61 citations from MEDLINE. Based on inclusion and exclusion criteria, 15 of 
these publications were included in this review (Figure 1). Four additional publications identified through 
reference list searching and one additional publication known to be relevant through prior knowledge were 
also included in the review. All of the included studies were published in peer-reviewed, scientific journals. 
 
Figure 1: modified PRISMA flow diagrama 
 
Secondary prophylaxis regimens and definitions of adherence 
Prescribed regimens of BPG varied between health authorities worldwide and included recommendations for 
2-weekly, 3-weekly, 4-weekly and monthly BPG. Additionally, there were a number of definitions of 
“adherence” to secondary prophylaxis employed in the reviewed literature. In some studies, a benchmark 
                                                        
a Modified from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.  
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percentage or fraction of recommended injections was defined as a case of “adherence”,[9, 10] whilst in 
others, rates of adherence were reported as a percentage of those who received 100% of their prescribed 
BPG, or a percentage of the total number of recommended injections administered to the study 
population.[11] Some authors utilized the terms “regular compliance”, “irregular compliance” and “non-
compliance” as defined by the WHO[12], whilst others created their own definitions of terms such as 
“complete compliance”, “partial compliance” and “dropout” to describe levels of adherence.[13] 
 
Rates of adherence 
Nineteen publications discussed rates of adherence to secondary prophylaxis; two of these articles utilized 
the same data set (Table 2). The majority of these were retrospective observational studies, with the 
exception of one randomized controlled trial measuring outcomes of patients on a 3-weekly versus a 4-
weekly regimen[13], one measure of past adherence by questionnaire[14], and one assessment of adherence 
based on qualitative interviews.[15] 
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Table 2: Rates of adherence to secondary prophylaxis for ARF And RHD 
                                                        
b Good-adherent defined as 80% of recommended BPG received 
c Poor-adherent defined as <80% of recommended BPG received 
d Adequate prophylaxis defined as >75% recommended BPG received 
Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Gasse et al., 
2013 [9] 
 
 
BioMed Central 
Public Health 
French 
Territory, 
Oceania 
Lifou, New 
Caledonia 
 
Patients recommended to 
receive 3-weekly BPG (n=70) 
Mean age 22.3 ± 11.6yrs 
(43%<16yrs); 63% females. 
Retrospective cohort study 
over 12 months in 2011 
54% good-adherentb 
46% poor-adherentc 
Mean adherence 77 ± 22% 
Median adherence 82.2% 
(IQR 76.5- 94.1) 
Median number of injections: 14 (range 2-
18) 
 
Remond et 
al., 2013 
[16] 
 
 
Internal Medicine 
Journal 
Australia, 
Oceania 
Kimberley Region, 
Western Australia; 
Far North 
Queensland 
Patients recommended to 
receive 3-4 weekly BPG 
(n=293) 
 
Retrospective observational 
study over 12 months 
(patients identified Nov 
2008 – Mar 2009) 
 
17.7% received ≥80% of recommended 
BPG 
Kearns et al., 
2010 [17] 
 
 
Rural and Remote 
Health 
Australia, 
Oceania 
Central Australia, 
Northern Territory 
 
 
Patients recommended to 
receive 4-weekly BPG (n=47] 
Median age 28yrs (range 8-
58yrs); 82% females. 
Retrospective observational 
study – adherence measured 
2 years before and after 
implementation of Full 
Moon Strategy in May 2006 
June 2004 - May 2006: 
47% overall uptake of recommended BPG 
(95% CI 44-51) 
May 2006 – June 2008: 
57% overall uptake of recommended BPG 
(95% CI 56-60) 
 
Stewart et 
al., 2007 
[18] 
 
 
Australian Journal 
of Rural Health 
Australia, 
Oceania 
Katherine, Northern 
Territory 
 
 
Patients recommended to 
receive monthly BPG (n=59) 
Age <18yrs 32%; 66% females. 
Retrospective observational 
study over 24 months from 
Sept 2002 to Sept 2004 
Mean adherence 56% of all recommended 
BPG 
Median adherence 54% of all 
recommended BPG (range 0-100%) 
Harrington 
et al., 2006 
[10] 
 
Medical Journal 
of Australia 
Australia, 
Oceania 
North East Arnhem 
Land, Northern 
Territory 
Patients recommended to 
receive monthly BPG (n=27) 
 
Retrospective observational 
study from Jan 2002 to Sept 
2003 
59% received adequate prophylaxisd 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Eissa et al., 
2005 [19] 
 
 
Australian and 
New Zealand 
Journal of 
Public Health 
Australia, 
Oceania 
Northern Territory Patients recommended to 
receive 3-4 weekly BPG 
(n=52) 
Male n=15 
 
Retrospective observational 
study over 12 months (patients 
identified in Aug 2004) 
22 (42%) patients received at least 80% of 
the minimum recommended dosese 
Median number of doses received in the 
previous 12 months: 9 
 
Mincham et 
al., 2002 
[20] 
Australian and 
New Zealand 
Journal of 
Public Health 
Australia, 
Oceania 
Kimberley, Western 
Australia 
Patients recommended to 
receive monthly BPG (n=78) 
 
Retrospective observational 
study of patients diagnosed 
with ARF or RHD from 1982 
to 1996 over 2 years from Jan 
1996 – Dec 1997 
 
67% of all prescribed BPG doses 
administered, with individuals receiving 8-
100% of doses prescribed. 
19% median injection interval 3.5-4.5 weeks 
Grayson et 
al., 2006 
[11] 
 
New Zealand 
Medical 
Journal 
New Zealand, 
Oceania 
Auckland Patients recommended to 
receive 3-4 weekly BPG 
(n=433 in 1998, n=428 in 
2000) 
Retrospective observational 
study of data from 1998 and 
2000 
 
86-96% total compliancef 
 
 
 
Seckeler et 
al., 2010 
[21] 
 
 
Pediatric 
Cardiology 
Common-
wealth of the 
United States of 
America, North 
America 
 
Northern Mariana 
Islands 
 
 
Patients recommended to 
receive 4-weekly BPG 
(n=144) 
Aged <21yrs  
 
Retrospective observational 
study from 1984 to 2006 
Mean adherence 58.3% of all recommended 
BPG  
Median adherence 69.2% of all 
recommended BPG (range 0-100%) 
Nordet et al., 
2008 [22] 
 
 
Cardiovascula
r Journal of 
Africa 
Cuba, North 
America 
Pinar del Rio School children 
recommended to receive 
monthly BPG (n=52 in 
1986, n=193 in 1996) 
Age range 5-15yrs 
 
Retrospective cross-sectional 
studies in 1986 and 1996 (first 
and last years of a 10 year 
prevention program) + 
comparison with a report on 
prevention activities in 2002 
1986: 
50% regular complianceg 
36.5% irregular complianceh 
13.5% non-compliancei 
1996: 
93.8% regular compliance 
6.2% irregular compliance 
2002: 
> 80% regular compliance 
                                                        
e Minimum recommended number of doses was 13 injections in 12 months 
f Total compliance defined as administration of all scheduled injections within predetermined time frames 
g Regular compliance defined as a minimum of 10-11 BPG injections received per year 
h Irregular compliance defined as 6-9 BPG injections received per year 
i Non-compliance defined as 5 BPG injections received per year 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Pelajo et al., 
2010 [23] 
Paediatric 
Rheumatology 
Brazil, South 
America 
Rio de Janeiro Patients recommended to 
receive monthly BPG 
(n=536) 
Mean age 13 ± 3.9yrs; 53% 
females. 
 
Retrospective observational 
study of patients with a 
diagnosis of ARF from 1985 
to 2005 
  
Non-adherencej detected in 35% (188 out of 
536) patients 
 
Robertson et 
al., 2005 
[15] 
 
 
South African 
Medical 
Journal 
South Africa, 
Africa 
Cape Town  Patients recommended to 
receive monthly BPG or oral 
penicillin (n=8; 7 receiving 
monthly BPG, 1 receiving 
oral penicillin) 
 
Qualitative semi-structured 
interviews with 
patients/guardians; date not 
specified 
 
In 7/8 cases, adherence with all 
recommended BPG was reported 
Bassili et al., 
2000 [24] 
 
 
Eastern 
Mediterranean 
Health Journal 
Egypt, Africa Alexandria Patients receiving secondary 
prophylaxis (n=127; 104 
prescribed 2-weekly BPG, 
14 prescribed 4-weekly BPG 
and 9 prescribed oral 
penicillin) Age 0-15yrs 
 
Retrospective observational 
study of patients over 6-12 
months (patients identified in 
Jan-Apr 1998) 
71.2% of patients compliantk in 2-weekly 
BPG group 
28.6% of patients compliant in 4-weekly 
BPG group 
 
Abdel-
Moula et al., 
1998 [14] 
 
 
Journal of the 
Egyptian 
Public Health 
Association 
 
Egypt, Africa Alexandria Patients receiving secondary 
prophylaxis (n=29; 20 
prescribed monthly BPG, 3 
prescribed 3-weekly BPG, 5 
prescribed 2-weekly BPG 
and 1 prescribed oral 
penicillin) 
Age range 6-16yrs 
 
Prospective case-control study 
with questionnaire regarding 
compliance over one year 
(patients identified in 
scholastic year 1993-1994) 
 
31% of patients not compliantl 
  
                                                        
j Patient classified as non-adherent if they missed or delayed >1 dose of BPG during a 6-month period (interval between appointments) 
k Patient considered compliant if received at least 11 BPG injections in the last 6 months or 22 BPG injections in the last year 
l Patient considered not compliant if received <80% of prescribed BPG injections per year 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Kassem et 
al., 1995 
[25] 
 
Egyptian Heart 
Journal 
Egypt, 
Africa 
Alexandria Patients recommended to receive 
secondary prophylaxis, 
unspecified regimen (n=86) 
Age range 16-32yrs (mean 
20.8±3.15yrs); 63% females 
Retrospective 
observational study over 
11-20 years (patients 
identified 1972-1980) 
 
Approximately 35% of patients 
uncompliantm 
Kumar et al., 
2002 [26] 
 
 
Indian Heart 
Journal 
India, Asia Ambala, Haryana Patients recommended to receive 
monthly BPG (n=257, 23-134 
patients eligible per year) 
Age 6-20yrs 70.8% 
 
Retrospective 
observational study 
1988-1999 
Mean yearly compliancen: 92%; annual 
variation 82.4-100% 
 
 
 
Kumar et al., 
1997 [27] 
 
 
Indian Heart 
Journal 
India, Asia Ambala, Haryana Patients recommended to receive 
monthly BPG (n=110 in 1995, 
n=17-106 in 1988-1994) 
In 1995, age range 6-50yrs 
(43.7% aged 6-15yrs, 43.7% aged 
16-25yrs); 48.2% male 
 
Retrospective 
observational study 
1988-1995 
1995: 83.6% of patients complianto  
1988-1994: >90% of patients compliant 
 
Lue et al., 
1996 [28] 
Lue et al, 
1994 [13] 
 
Journal of 
Pediatrics 
Taiwan, 
Asia 
Taipei Patients prescribed 3-weekly and 
4-weekly BPG (n=249; 124 
prescribed 3-weekly BPG, 125 
prescribed 4-weekly BPG 
Age range 3-25yrs 
Randomized controlled 
trial 1979-1989 
3-weekly BPG group: 66.9% stay-in 
(complete) compliancep, 15.3% partial 
complianceq, 9.7% dropoutr 
4-weekly BPG group: 73.6% stay-in 
(complete) compliance, 15.2% partial 
compliance, 9.2% dropout 
 
 
  
                                                        
m Definition of uncompliant not provided 
n Compliance defined as percentage of those eligible for secondary prophylaxis who received secondary prophylaxis 
o Missed no more than 1 BPG injection per year 
p Complete compliance defined as  1 BPG injection missed per year 
q Partial compliance defined as 2-3 BPG injections missed per year 
r Dropout defined as  4 BPG injections missed per year 
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Factors associated with adherence 
Ten of the included studies discussed factors associated with adherence to secondary prophylaxis (Table 3). 
Qualitative, semi-structured interviews were conducted in seven of these studies, two of which additionally 
included questionnaires. Multivariate logistic regression was performed in one study[9] and other inferential 
statistical analysis was performed in two studies.[18, 19]
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Table 3: Factors associated with adherence to secondary prophylaxis for ARF and RHD 
Authors Source Location Prophylaxis regimen/Study 
population 
Study design Summary of Findings 
Gasse et al., 
2013 [9] 
 
 
BioMed Central 
Public Health 
Lifou, New 
Caledonia 
 
 
Patients recommended to 
receive 3-weekly BPG 
(n=70) 
Mean age 22.3 ± 11.6yrs 
(43%<16yrs); 63% females. 
Retrospective cohort 
study over 12 months in 
2011 
Multivariate logistic 
regression model 
Factors protective against poor adherence: a household with >5 people 
(odds ratio 0.25, 95% CI 0.08-0.75), a previous medical history of 
symptomatic ARF (odds ratio 0.20, 95% CI 0.04 to 0.98), adequate 
healthcare coverage (odds ratio 0.21, 95% CI 0.06-0.72). 
Stewart et 
al., 2007 
[18] 
 
 
Australian Journal 
of Rural Health 
Katherine, 
Northern 
Territory, 
Australia 
Patients recommended to 
receive monthly BPG (n=59) 
Age <18yrs 32%; 66% 
females. 
Retrospective 
observational study over 
24 months from Sept 
2002 to Sept 2004 
In those who received 50% of prescribed BPG, non-significant trend 
towards improved adherence seen in patients aged <18 years 
(RR=1.26) and those who attended a health clinic more frequently for 
other reasons (RR=1.42). 
Patients with more severe disease less likely to receive monthly BPG 
(RR=0.60). 
Men and women equally likely to receive monthly BPG (RR=1.09). 
Harrington 
et al., 2006 
[10] 
 
 
Medical Journal 
of Australia 
North East 
Arnhem Land, 
Northern 
Territory, 
Australia 
Patients recommended to 
receive monthly BPG, 
relatives and health care 
workers (n=51; 15 patients, 
18 relatives, 18 health care 
workers) 
Patient age range 20-60yrs 
(range of time since 
diagnosis 1-30yrs); female 
n=45, male n=6 
Qualitative semi-
structured interviews 
conducted Apr-Aug 2003 
 
Staff factors promoting uptake: appropriately trained, socially and 
culturally competent staff, an active recall system, staff willingness to 
treat the patient at home. 
Patient factors promoting uptake: an appropriate location for receiving 
injections, belief that the disease is chronic and serious, confidence in 
the health service and receipt of holistic care, family support for and 
belief in the efficacy of treatment. 
Staff factors inhibiting uptake: negative perception of the secondary 
prophylaxis program, conflicting priorities for staff, no effective 
strategy for dealing with absent patients, staff fatigue and frustration 
Patient factors inhibiting uptake: conscientious refusal of treatment, 
inconvenience to the patient, not “belonging” to the health service, lack 
of family support, lack of confidence in the treatment. 
Factors not clearly related to treatment uptake: patient biomedical 
understanding of the disease, taking responsibility for health and 
perception of painfulness of the treatment. 
Eissa et al., 
2005 [19] 
 
 
Australian and 
New Zealand 
Journal of Public 
Health 
Northern 
Territory, 
Australia 
Patients recommended to 
receive 3-4 weekly BPG 
(n=52) 
Male n=15 
Retrospective 
observational study over 
12 months (patients 
identified in Aug 2004) 
Females significantly more likely to receive treatment than males 
(p=0.004). 
Higher adherence rate (median doses 10/year) in moderate or severe 
disease compared with mild disease (median doses 8/year). 
Mincham et 
al., 2003 
[29] 
 
Australian Journal 
of Rural Health 
Kimberley, 
Western 
Australia, 
Australia 
Patients/parents of patients 
recommended to receive 
monthly BPG (n=7) 
Qualitative semi-
structured interviews in 
1998 
Compliance with secondary prophylaxis associated with positive 
patient–staff interactions. 
Living in a remote location was a negative influence. 
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Participants had variable levels of understanding of the disease and 
need for BPG. 
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Authors Source Location Prophylaxis regimen/Study 
population 
Study design Summary of Findings 
Grayson et 
al., 2006 
[11] 
New Zealand 
Medical Journal 
Auckland, 
New Zealand 
Nurses involved with delivery 
of 3-4 weekly BPG (n=9) 
Qualitative semi-
structured interviews; 
date not specified 
Presence of community health workers, a rheumatic fever resource 
nurse and communication from other services used by rheumatic fever 
patients impacted positively on the delivery of secondary prophylaxis. 
Robertson et 
al., 2005 
[15] 
 
 
South African 
Medical Journal 
Cape Town, 
South Africa 
Caregivers of patients (n=8); 
physicians (n=24)  
Qualitative semi-
structured interviews 
with caregivers of 
patients + 24 
physician 
questionnaires; date 
not specified 
There was very poor knowledge of the disease amongst 
patients/guardians, however this was not associated with non-
adherence to secondary prophylaxis. 
Bassili et al., 
2000 [24] 
 
 
Eastern 
Mediterranean 
Health Journal 
Alexandria, 
Egypt 
Caregivers of children and 
children receiving secondary 
prophylaxis (n=127; 104 
prescribed 2-weekly BPG, 14 
prescribed 4-weekly BPG and 9 
prescribed oral penicillin) 
Retrospective chart 
review of compliance 
over 6-12 months 
(patients identified in 
Jan-Apr 1998) + 
questionnaire based 
qualitative interviews 
in Jan-Apr 1998 
Stepwise logistic 
regression 
Non-compliance was more common among children whose parents had 
lower educational and occupational levels, those whose parents had 
only fair to poor knowledge of the disease, those living in semi-urban 
and rural areas, those with health insurance and those whose families 
were not satisfied with the health care provided. 
Kumar et al., 
2002 [26] 
 
 
Indian Heart 
Journal 
Ambala, 
Haryana, India 
Patients recommended to 
receive monthly BPG 
(n=unclear; 40 non-compliant 
patients + an unknown number 
of compliant patients – total 
number of participants in 
associated quantitative study = 
257) 
Qualitative, semi-
structured interviews 
in 1999 
Reasons for non-compliance: fear/dislike of injections, belief that 
injections were no longer required given seemingly good health, lack 
of awareness of the importance of secondary prophylaxis and services 
not available locally. 
Kumar et al., 
1997 [27] 
 
 
Indian Heart 
Journal 
Haryana, India Patients recommended to 
receive monthly BPG (n=110) 
Mean age 18.4 ± 8.6yrs; 48.2% 
male. 
 
Qualitative semi-
structured interviews 
conducted in 1995 
Reasons for non-compliance: private doctors ceasing BPG injections, 
unsupportive family members, a disinterest in BPG injections and long 
distances of travel to health clinics. 
No significant association between non-adherence and low 
socioeconomic background. 
No significant association between non-adherence and level of 
education of parents. 
 17 
Quality assessment 
Use of the quality assessment tool demonstrated the methodological quality of each of the included studies 
(Table 4).
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Table 4: Qualityative assessment 
Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Abdel-
Moula et 
al., 1998 
[14] 
Yes Yes Yes 
 
Yes Yes Yes No No Not relevant Not relevant 
Bassili et 
al., 2000 
[24] 
Yes Yes No Yes Not relevant Yes Yes Yes Not relevant Not relevant 
Eissa et 
al., 2005 
[19] 
Yes Yes No Yes Unknown Yes Yes No Not relevant Not relevant 
Gasse et 
al., 2013 
[9] 
Yes Yes No Yes Yes Yes Yes Yes Not relevant Not relevant 
Grayson et 
al., 2006 
[11] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes No No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Harrington 
et al., 
2006[10] 
Yes Yes Not relevant Not relevant Not relevant No No No Yes Yes 
Kassem et 
al., 1995 
[25] 
Yes No No Unknown Not relevant No No No Not relevant Not relevant 
Kearns et 
al., 2010 
[17] 
Yes Yes Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant No Yes No Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
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Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Kumar et 
al., 2002 
[26] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes Yes  No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Kumar et 
al., 1997 
[27] 
Yes Yes Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes Yes No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Lue et al., 
1996 [28]; 
Lue et al., 
1994 [13] 
Yes Yes No 
 
Yes Yes Yes Yes No Not relevant Not relevant 
Mincham 
et al., 
2003 [29] 
Yes No Not relevant Not relevant Not relevant Yes No No Yes Yes 
Mincham 
et al., 
2002 [20] 
Yes Yes No Yes Not relevant Yes No No Not relevant Not relevant 
Nordet et 
al., 2008 
[22] 
Yes Yes No Yes Not relevant Yes Yes 
 
No Not relevant Not relevant 
Pelajo et 
al., 2010 
[23] 
Yes Yes No Yes Yes No Yes No Not relevant Not relevant 
Remond et 
al., 2013 
[16] 
Yes Yes No Unknown Not relevant Yes Yes No Not relevant Not relevant 
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Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Robertson 
et al., 
2005[15] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes No No Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Seckeler et 
al., 2010 
[21] 
Yes Yes No Yes Yes Yes Yes No Not relevant Not relevant 
Stewart et 
al., 2007 
[18] 
Yes Yes No Yes Yes Yes Yes No Not relevant Not relevant 
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Discussion 
Over the last 20 years, studies addressing adherence to secondary prophylaxis for ARF/RHD have been 
conducted in India, Egypt, South Africa, Brazil, Cuba, the Northern Mariana Islands, Australia, New 
Zealand, New Caledonia and Taiwan. On review of this literature, there was a range of adherence to 
different regimens of BPG prescribed as secondary prophylaxis worldwide. Whilst a small number of 
studies conducted in Cuba, India and New Zealand reported good overall adherence, adherence 
measured in the majority of studies was sub-optimal. An individual range of 0-100% of prescribed 
injections also indicated that despite overall adherence rates, some patients received inadequate BPG 
injections whilst others received appropriate prophylaxis. Adherence to BPG was not evidently better 
or worse amongst minority groups and migrants in developed countries compared with adherence in 
developing countries. Very few studies assessed adherence over time in comparable populations with 
the same definitions, so global trends regarding this could not be established. In the Cuban study, 
adherence improved over time from 50% regular compliance in 1986 to >80% regular compliance in 
2002,[22] whilst Indian studies demonstrated an adherence decline from 100% compliance in 1988 to 
82.4% compliance in 1999.[26, 27] 
 
Factors associated with lower adherence 
In underprivileged settings where ARF and RHD remain prevalent, there are a number of interrelated 
factors associated with low adherence to secondary prophylaxis. Rurality with limited access to health 
care was one important theme in four studies, one involving logistic regression analysis (Bassili et al.) 
and three others including qualitative semi-structured interviews. Bassili et al. reported non-adherence 
to be more common amongst children in semi-urban and rural areas,[24] Mincham et al. found that 
living in a remote location was a negative influence on adherence[29] and two Indian studies identified 
lack of local services and long distances of travel as reasons for non-adherence.[26, 27] It follows that 
for patients living in rural and remote areas with lesser access to health care, adhering to secondary 
prophylaxis regimens may be more difficult. 
 
Negative patient, staff and health service interactions were also reported as contributors to non-
adherence in three studies. Bassili et al.’s logistic regression analysis found non-adherence to be more 
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common among children whose families were not satisfied with the health care provided,[24] and 
qualitative semi-structured interviews performed by Mincham et al. and Harrington et al. in Australia 
highlighted that negative patient-staff interactions, limited confidence in the treatment and a lack of 
sense of “belonging” to the health service could reduce adherence.[10, 29] Mincham et al. and 
Harrington et al.’s studies also discussed staff factors inhibiting uptake, including the transient nature 
of staff in remote settings, a negative perception of the secondary prophylaxis program, conflicting 
health priorities, and no effective strategy for dealing with absent patients leading to staff frustration 
and fatigue.[10, 29] These findings may be most relevant to Australian Indigenous populations and 
other minority groups in developed countries, where a difference in cultural values, attitudes and 
beliefs between the patient/caregiver and health care provider may exist. In Mincham et al.’s study, 
lack of an effective reminder system for due injections additionally led to non-adherence to secondary 
prophylaxis.[29] 
  
Other factors associated with non-adherence included lack of family support (observed in two 
qualitative studies)[10, 27] a disinterest in or conscientious refusal of treatment (discussed in two 
qualitative studies)[10, 27] and inconvenience of the treatment or treatment interference with personal 
priorities (identified in two qualitative studies).[10, 29]  
 
On the field, lack of BPG supply is another known factor leading to lower rates of BPG administration, 
however this was not raised in the studies reviewed. In prospective studies, this is likely because BPG 
supply was ensured for the study population. In retrospective observational studies, it may be that 
supply was assumed to have been adequate by the researchers, and in qualitative interviews and 
questionnaires perhaps the focus was on individual and health service factors, without consideration of 
pharmaceutical supply. 
 
Factors associated with higher adherence 
Factors associated with higher adherence were also identified in the literature reviewed. Positive 
patient, staff and health system interactions promoted adherence in three small qualitative studies in 
Australia and New Zealand. Mincham et al. found that adherence was closely linked with positive 
patient-staff interactions[29] whilst Harrington et al. identified that patient confidence in the health 
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service and receipt of holistic care, as well as family support for and belief in the treatment, were 
important to adherence.[10] The presence of appropriately trained, socially and culturally competent 
staff was discussed by Harrington et al. as a factor associated with higher adherence[10] and supported 
by Grayson et al.’s report that the presence of community health workers and a rheumatic fever 
resource nurse impacted positively on adherence.[11] Harrington et al. additionally found that an 
appropriate location for injections and staff willingness to treat patients at home promoted uptake.[10] 
These study findings may have greater applicability in countries similar to Australia and New Zealand, 
where ARF/RHD is most prevalent amongst migrant and minority groups. In Harrington et al.’s study, 
recall systems for patients with due BPG injections were also associated with higher adherence.[10]  
 
Opportunistic communications may improve adherence to secondary prophylaxis. A qualitative study 
by Grayson et al. found that communication from other services used by rheumatic fever patients 
impacted positively on adherence,[11] and Stewart et al.’s retrospective study involving inferential 
analysis described a non-significant trend towards improved adherence in patients who attended a 
health clinic more frequently for reasons other than secondary prophylaxis.[18] 
 
Patient demographic factors including younger age and greater number of people per household could 
also positively influence adherence to secondary prophylaxis. Stewart et al. found a non-significant 
trend towards improved adherence in patients aged <18 years compared with patients aged ≥18 years 
amongst those who received ≥50% of prescribed BPG.[18] Perhaps this is because parents/caregivers 
are overseeing adherence in younger patients; young adults newly responsible for their own health care 
may have a tendency towards non-adherence. Meanwhile, Gasse et al.’s retrospective study involving 
multivariate logistic regression analysis identified that a household with ≥6 people was protective 
against poor adherence. It is postulated that this may be because older siblings in the household are 
able to assist with health care seeking.[9] 
 
 
Factors with unclear association to adherence 
A number of factors had an unclear association with adherence to secondary prophylaxis. Biomedical 
knowledge of ARF and RHD was poor amongst patients and their families, yet whilst Bassili et al. 
described non-adherence to be more common in patients who’s parents had only a fair to poor 
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knowledge of the disease,[24] Robertson et al. reported no association between knowledge of the 
disease and adherence.[10, 15, 29] Harrington et al. found that an understanding of the chronic and 
serious nature of the disease was more relevant than biomedical knowledge.[10] The fact that indicated 
BPG injections were ceased by patients due to seemingly good health in Kumar et al.’s study also 
suggests that a level of understanding of the disease course is needed.[26] Certainly, delivering 
education was thought to be a worthwhile intervention by many and remains an intuitively key aspect 
of health care.[9, 26, 29] Conflicting results regarding the relationship between patients’ parents’ level 
of education and adherence to secondary prophylaxis were also reported, with Bassili et al. describing 
non-adherence to be more common amongst children whose parents had lower levels of education and 
occupation[24] and Kumar et al. finding no association between parents’ level of education and 
patients’ adherence to secondary prophylaxis.[27] 
 
Certain patient demographic and clinical factors also have an unclear association with secondary 
prophylaxis adherence. Eissa et al. found that service delivery was better for females than males,[19] 
however Stewart et al. found that males and females were equally likely to receive monthly BPG.[18] 
Gasse et al. reported adequate healthcare coverage was protective against poor adherence, [9] yet 
Bassili et al. described non-adherence as more common in children with health insurance compared to 
those without.[24] Eissa et al. also found that adherence was higher among patients with moderate or 
severe disease compared to patients with mild disease.[19] In similar vein, Gasse et al. found that a 
previous medical history of symptomatic ARF was protective against poor adherence.[9] However, in 
Stewart et al.’s study patients with more severe disease were less likely to receive monthly BPG.[18] 
 
Pain and dislike of injections as well as the issue of responsibility for injection delivery are other 
important considerations in adherence. According to one qualitative study, pain associated with 
injections was not necessarily a deterrent to secondary prophylaxis uptake,[10] however in two 
qualitative studies, fear/dislike of injections was given as a reason for non-adherence.[26, 27] 
Harrington et al. and Mincham et al. both commented on the balance of health seeking and health 
delivery responsibility between patients, caregivers and health staff, [10, 29] A common understanding 
of roles and responsibilities in a given community appears important to ensuring BPG administration 
occurs.[10, 29]  This balance may differ in urban compared to rural settings, especially in Australia 
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where historically a more paternalistic approach to rural Indigenous health care delivery has been 
taken.[10] Adherence to secondary prophylaxis for ARF and RHD is evidently a complex and multi-
factorial issue. 
 
 
Strengths and weaknesses 
To the best of our knowledge, this is the first systematic review exploring rates of adherence and 
factors associated with adherence to secondary prophylaxis for ARF and RHD. Our review was 
conducted using PRISMA guidelines to ensure a transparent and complete reporting system. However, 
formal data synthesis with meta-analysis was unable to be performed as authors used different study 
designs and definitions of adherence, and there were differing regimens for secondary prophylaxis 
recommended worldwide. Despite this limitation, our use of a modified validated tool for 
methodological quality assessment allows for the appraisal of included studies.  
 
When examining factors associated with adherence to secondary prophylaxis, it should be taken into 
consideration that the number of studies from different geographical regions is not proportional to the 
prevalence of ARF and RHD in those regions. There were six studies from Oceania (four conducted in 
Australia), two from India, one from Egypt and one from South Africa, whereas India has the highest 
prevalence of ARF/RHD among these locations. Care must be taken when interpreting and applying 
review findings within a local context. However, an overlap in factors pertinent to adherence in the 
different study regions, such as the effect of rurality and access to health services, suggests that some 
findings may be universally relevant. 
 
 
What is the current knowledge gap? 
Knowledge of rates of adherence to secondary prophylaxis for ARF and RHD promotes an accurate 
appreciation of the problem of poor uptake. Further studies reporting rates of adherence worldwide are 
hence warranted, as these data are not available in many countries and may be outdated in others. 
 
Future research may also further explore factors associated with adherence to BPG injections given the 
limited number of studies addressing this worldwide and global variation in population sociocultural 
demographics. An understanding of factors associated with adherence can be used by doctors, nurses, 
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community health workers and policy makers to improve service delivery. Patient self-awareness of 
these factors may also assist in overcoming barriers to receiving secondary prophylaxis. 
 
Can the situation be improved? 
Interventions to improve adherence to secondary prophylaxis that could be adopted by established 
ARF/RHD control programs include ensuring an effective active recall system,[9, 23] involving 
community health workers[30] and delivering education about the disease and its management.[9] It is 
commonly said, “What gets measured gets managed.” Thus, it may be worthwhile to record reasons for 
failure of patients to attend for BPG injections. This could be made part of a specific protocol for when 
secondary prophylaxis is missed, with individual follow-up and troubleshooting by a community health 
worker who has knowledge of local sociocultural and geographic influences. Facilitating a holistic 
approach in service delivery so that patients and their families feel supported and confident in the care 
received is vital.[10, 24, 27] It should be noted that these interventions can only be achieved with 
adequate and sustained financial support and staff resources.[19] 
 
 
Conclusion 
Current literature provides some insight into levels of adherence and factors associated with adherence 
to secondary prophylaxis for ARF and RHD. However, further studies are warranted to develop a 
better understanding of current adherence rates and factors associated with adherence worldwide. 
Improved delivery of secondary prophylaxis is necessary to ensure best health outcomes for affected 
pediatric and young adult populations. Interventions to achieve this should target patient demographic, 
clinical, sociocultural and health service delivery factors with known association to adherence, and 
may include implementation of an active recall system, provision of holistic care, involvement of 
community health workers and delivery of ARF/RHD health education.  
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Abstract 
Background: Optimal delivery of regular benzathine penicillin G (BPG) injections prescribed as secondary 
prophylaxis for acute rheumatic fever (ARF) and rheumatic heart disease (RHD) is vital to preventing disease 
morbidity and cardiac sequelae in affected pediatric and young adult populations. However, poor uptake of 
secondary prophylaxis remains a significant challenge to ARF/RHD control programs.  
Objective: In order to facilitate better understanding of this challenge and thereby identify means to improve 
service delivery, this systematic literature review explored rates of adherence and factors associated with 
adherence to secondary prophylaxis for ARF and RHD worldwide. 
Methods: MEDLINE was searched for relevant primary studies published in the English language from 
1994-2014, and a search of reference lists of eligible articles was performed. The methodological quality of 
included studies was evaluated using a modified assessment tool. 
Results: Twenty studies were included in the review. There was a range of adherence to varying regimens of 
secondary prophylaxis reported globally, and a number of patient demographic, clinical, socio-cultural and 
health care service delivery factors associated with adherence to secondary prophylaxis were identified. 
Conclusion: Insights into factors associated with lower and higher adherence to secondary prophylaxis may 
be utilized to facilitate improved delivery of secondary prophylaxis for ARF and RHD. Strategies may 
include ensuring an effective active recall system, providing holistic care, involving community health 
workers and delivering ARF/RHD health education. 
 
Keywords 
Acute rheumatic fever, rheumatic heart disease, benzathine penicillin, benzathine benzylpenicillin, penicillin 
G benzathine, secondary prophylaxis, adherence, compliance 
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Introduction 
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are a cause of significant morbidity and 
cardiac mortality amongst pediatric and young adult populations in developing countries, migrants from 
these nations and minority populations in developed countries.[1] The annual worldwide incidence of ARF 
has been estimated at over 471 000,[2] with major and minor clinical manifestations including carditis, 
arthritis, chorea, erythema marginatum, subcutaneous nodules, arthralgia and fever.[3] RHD resulting from 
recurrent episodes of ARF has an estimated prevalence of at least 15.6 million people globally.[2] An 
approximate worldwide mortality of 233 000 people per annum[2] is attributed to complications of valvular 
disease including arrhythmias, heart failure, thromboembolism and infective endocarditis.[3] 
 
Secondary prophylaxis with regular intramuscular injections of benzathine penicillin G (BPG) is a key 
component of ARF and RHD control programs. This approach aims to prevent group A beta-hemolytic 
streptococci (GAS) infections and subsequent recurrent episodes of ARF.[4] The World Health Organization 
(WHO) recommends 3-4 weekly BPG continued for a duration dependent on factors including age, time 
since the last episode of ARF, risk of streptococcal infections in the area and presence of RHD.[4] According 
to WHO guidelines, secondary prophylaxis should continue for at least 5 years after the last episode of ARF 
or until the age of 18 years (whichever is longer) and for a greater length of time in cases of carditis or 
RHD.[4, 5] However, local health authorities give slightly varying recommendations for the frequency and 
duration of BPG injections.[5]  
 
Low adherence with secondary prophylaxis is one of the main challenges to effective control of ARF and 
RHD.[4] To the best of our knowledge, a systematic literature review to summarize what is known regarding 
rates of adherence and factors associated with adherence to secondary prophylaxis does not exist.  This study 
aims to systematically summarize and evaluate published rates of adherence and factors associated with 
adherence to BPG injections prescribed as secondary prophylaxis for ARF and RHD, and thereby identify 
means to improve secondary prophylaxis interventions. In contrast to other studies of adherence in chronic 
disease management, of particular interest and importance in this review is the focus of adherence amongst 
poor and underserved population groups. 
 
Methods 
Protocol and focus 
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This systematic review has been conducted using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.[6] The review focuses on studies that explored rates of adherence and 
factors associated with adherence to BPG injections recommended as secondary prophylaxis for ARF and 
RHD worldwide. 
 
Search criteria 
A search of the MEDLINE database via OvidSP was conducted on 28 June 2014. All articles written in the 
English language between January 1, 1994 and June Week 3, 2014, using the Medical Subject Headings 
(MeSH) and keywords, (“acute rheumatic fever” OR “rheumatic fever” OR “rheumatic heart disease”) AND 
(“secondary prophylaxis” OR “secondary prevention” OR “benzathine penicillin G” OR “penicillin G 
benzathine” OR “benzathine penicillin” OR “benzathine benzylpenicillin” OR “disease management” OR 
“management”) AND (“patient compliance” OR “compliance” OR “non-compliance” OR “noncompliance” 
OR “treatment refusal” OR “guideline adherence” OR “medication adherence” OR “adherence” OR “non-
adherence” OR “nonadherence” OR “alignment” OR “non-alignment” OR “nonalignment”), were retrieved. 
A single investigator (PK) screened the titles and abstracts of all retrieved citations and performed full text 
reviews of relevant studies. Reference lists of relevant studies were hand searched to identify additional 
relevant publications. 
 
Eligibility criteria 
Eligibility criteria were determined with expert input from two pediatricians. Primary studies published from 
January 1, 1994 to June Week 3, 2014, were included in the literature review if they reported rates of 
adherence to secondary prophylaxis for ARF/RHD or discussed factors associated with adherence to BPG 
injections recommended as secondary prophylaxis for ARF/RHD.  
 
Articles that were not primary studies or were irrelevant to the focus of this review were excluded. This 
included articles written about the epidemiology and clinical presentation of ARF/RHD, symptomatic 
treatment of ARF episodes, the efficacy of differing antibiotic regimens prescribed as secondary prophylaxis 
for ARF/RHD and guidelines for delivery of secondary prophylaxis for ARF/RHD, without reference to rates 
of adherence or factors associated with adherence to secondary prophylaxis for ARF/RHD. 
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Data extraction and quality assessment 
One investigator (PK) used a standardized sheet to extract data from included studies. Data extracted 
included the author, year of publication, source, location of study, study design and study population 
characteristics. Study findings addressing rates of adherence to secondary prophylaxis for ARF/RHD and 
factors associated with adherence to secondary prophylaxis for ARF/RHD were also summarized. 
 
We created a quality assessment tool to evaluate the methodological quality of included studies incorporating 
validated elements of Pluye et al.’s Mixed Methods Assessment Tool (MMAT)[7] and Wells et al.’s 
checklists for non-randomized studies in systematic reviews[8]. Our tool assessed methodological quality in 
ten domains including the incorporation of clear study objectives with suitable data collection, clarity of 
adherence definition, sample size adequacy, recruitment method, comparability of participant groups, 
outcome measure rate/response rate, use of inferential statistical analysis, inclusion of multivariate analysis, 
consideration given to the contextual relation of findings and consideration given to researchers’ influence on 
study findings (Table 1).  
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Table 1: Quality assessment tool 
Assessment criteria Yes No 
Clear research objectives 
with suitable data collection 
Research objectives clearly outlined 
and data collected addresses 
research objectives 
Research objectives not clearly 
outlined or data collected does not 
adequately address research objectives 
Definition of adherence to 
secondary prophylaxis clear 
Adherence and non-adherence or 
levels of adherence to secondary 
prophylaxis clearly defined 
Adherence, non-adherence or levels of 
adherence to secondary prophylaxis not 
clearly defined 
Sample size calculation 
reported and target sample 
size reached 
Sample size calculation performed 
and target sample size reached 
Sample size calculation not performed 
or reported, or sample size calculation 
performed and target sample size not 
reached 
Recruitment of participants 
used probability sampling 
All or a randomly selected 
proportion of all persons on a 
register included 
Neither all nor a randomly selected 
proportion of all persons on a register 
included 
Participant groups 
comparable 
Key demographic information 
comparing participant groups is 
presented and there are no obvious 
dissimilarities that may account for 
differences in outcomes, or 
dissimilarities are taken into 
account in data analysis. 
There are apparent dissimilarities 
between participant groups that may 
account for differences in outcomes 
and these dissimilarities are not taken 
into account in data analysis. 
Outcome data 
complete/Response rate 
acceptable 
Outcome data ≥80% 
complete/Response rate ≥60% 
Outcome data <80% 
complete/Response rate <60% 
Any inferential statistical 
analysis 
Inferential statistical analysis 
performed 
Inferential statistical analysis not 
performed 
Multivariate analysis of 
factors associated with 
adherence 
Multivariate analysis of factors 
associated with adherence 
performed 
Multivariate analysis of factors 
associated with adherence not 
performed 
Consideration given to 
contextual relation of 
findings (qualitative studies) 
Explanation of how study findings 
relate to the study context or 
context characteristics given 
Explanation of how study findings 
relate to the study context or context 
characteristics not given 
Consideration given to 
researchers’ influence in 
relation to findings 
(qualitative studies) 
Researchers critically explained 
how findings relate to their 
perspectives, roles and interactions 
with participants 
Researchers did not critically explain 
how findings relate to their 
perspectives, roles and interactions 
with participants 
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Results 
Search results and quality assessment 
Electronic searching retrieved 61 citations from MEDLINE. Based on inclusion and exclusion criteria, 15 of 
these publications were included in this review (Figure 1). Four additional publications identified through 
reference list searching and one additional publication known to be relevant through prior knowledge were 
also included in the review. All of the included studies were published in peer-reviewed, scientific journals. 
 
Figure 1: modified PRISMA flow diagrama 
 
Secondary prophylaxis regimens and definitions of adherence 
Prescribed regimens of BPG varied between health authorities worldwide and included recommendations for 
2-weekly, 3-weekly, 4-weekly and monthly BPG. Additionally, there were a number of definitions of 
“adherence” to secondary prophylaxis employed in the reviewed literature. In some studies, a benchmark 
                                                        
a Modified from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.  
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percentage or fraction of recommended injections was defined as a case of “adherence”,[9, 10] whilst in 
others, rates of adherence were reported as a percentage of those who received 100% of their prescribed 
BPG, or a percentage of the total number of recommended injections administered to the study 
population.[11] Some authors utilized the terms “regular compliance”, “irregular compliance” and “non-
compliance” as defined by the WHO[12], whilst others created their own definitions of terms such as 
“complete compliance”, “partial compliance” and “dropout” to describe levels of adherence.[13] 
 
Rates of adherence 
Nineteen publications discussed rates of adherence to secondary prophylaxis; two of these articles utilized 
the same data set (Table 2). The majority of these were retrospective observational studies, with the 
exception of one randomized controlled trial measuring outcomes of patients on a 3-weekly versus a 4-
weekly regimen[13], one measure of past adherence by questionnaire[14], and one assessment of adherence 
based on qualitative interviews.[15] 
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Table 2: Rates of adherence to secondary prophylaxis for ARF And RHD 
                                                        
b Good-adherent defined as 80% of recommended BPG received 
c Poor-adherent defined as <80% of recommended BPG received 
d Adequate prophylaxis defined as >75% recommended BPG received 
Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Gasse et al., 
2013 [9] 
 
 
BioMed Central 
Public Health 
French 
Territory, 
Oceania 
Lifou, New 
Caledonia 
 
Patients recommended to 
receive 3-weekly BPG (n=70) 
Mean age 22.3 ± 11.6yrs 
(43%<16yrs); 63% females. 
Retrospective cohort study 
over 12 months in 2011 
54% good-adherentb 
46% poor-adherentc 
Mean adherence 77 ± 22% 
Median adherence 82.2% 
(IQR 76.5- 94.1) 
Median number of injections: 14 (range 2-
18) 
 
Remond et 
al., 2013 
[16] 
 
 
Internal Medicine 
Journal 
Australia, 
Oceania 
Kimberley Region, 
Western Australia; 
Far North 
Queensland 
Patients recommended to 
receive 3-4 weekly BPG 
(n=293) 
 
Retrospective observational 
study over 12 months 
(patients identified Nov 
2008 – Mar 2009) 
 
17.7% received ≥80% of recommended 
BPG 
Kearns et al., 
2010 [17] 
 
 
Rural and Remote 
Health 
Australia, 
Oceania 
Central Australia, 
Northern Territory 
 
 
Patients recommended to 
receive 4-weekly BPG (n=47] 
Median age 28yrs (range 8-
58yrs); 82% females. 
Retrospective observational 
study – adherence measured 
2 years before and after 
implementation of Full 
Moon Strategy in May 2006 
June 2004 - May 2006: 
47% overall uptake of recommended BPG 
(95% CI 44-51) 
May 2006 – June 2008: 
57% overall uptake of recommended BPG 
(95% CI 56-60) 
 
Stewart et 
al., 2007 
[18] 
 
 
Australian Journal 
of Rural Health 
Australia, 
Oceania 
Katherine, Northern 
Territory 
 
 
Patients recommended to 
receive monthly BPG (n=59) 
Age <18yrs 32%; 66% females. 
Retrospective observational 
study over 24 months from 
Sept 2002 to Sept 2004 
Mean adherence 56% of all recommended 
BPG 
Median adherence 54% of all 
recommended BPG (range 0-100%) 
Harrington 
et al., 2006 
[10] 
 
Medical Journal 
of Australia 
Australia, 
Oceania 
North East Arnhem 
Land, Northern 
Territory 
Patients recommended to 
receive monthly BPG (n=27) 
 
Retrospective observational 
study from Jan 2002 to Sept 
2003 
59% received adequate prophylaxisd 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Eissa et al., 
2005 [19] 
 
 
Australian and 
New Zealand 
Journal of 
Public Health 
Australia, 
Oceania 
Northern Territory Patients recommended to 
receive 3-4 weekly BPG 
(n=52) 
Male n=15 
 
Retrospective observational 
study over 12 months (patients 
identified in Aug 2004) 
22 (42%) patients received at least 80% of 
the minimum recommended dosese 
Median number of doses received in the 
previous 12 months: 9 
 
Mincham et 
al., 2002 
[20] 
Australian and 
New Zealand 
Journal of 
Public Health 
Australia, 
Oceania 
Kimberley, Western 
Australia 
Patients recommended to 
receive monthly BPG (n=78) 
 
Retrospective observational 
study of patients diagnosed 
with ARF or RHD from 1982 
to 1996 over 2 years from Jan 
1996 – Dec 1997 
 
67% of all prescribed BPG doses 
administered, with individuals receiving 8-
100% of doses prescribed. 
19% median injection interval 3.5-4.5 weeks 
Grayson et 
al., 2006 
[11] 
 
New Zealand 
Medical 
Journal 
New Zealand, 
Oceania 
Auckland Patients recommended to 
receive 3-4 weekly BPG 
(n=433 in 1998, n=428 in 
2000) 
Retrospective observational 
study of data from 1998 and 
2000 
 
86-96% total compliancef 
 
 
 
Seckeler et 
al., 2010 
[21] 
 
 
Pediatric 
Cardiology 
Common-
wealth of the 
United States of 
America, North 
America 
 
Northern Mariana 
Islands 
 
 
Patients recommended to 
receive 4-weekly BPG 
(n=144) 
Aged <21yrs  
 
Retrospective observational 
study from 1984 to 2006 
Mean adherence 58.3% of all recommended 
BPG  
Median adherence 69.2% of all 
recommended BPG (range 0-100%) 
Nordet et al., 
2008 [22] 
 
 
Cardiovascula
r Journal of 
Africa 
Cuba, North 
America 
Pinar del Rio School children 
recommended to receive 
monthly BPG (n=52 in 
1986, n=193 in 1996) 
Age range 5-15yrs 
 
Retrospective cross-sectional 
studies in 1986 and 1996 (first 
and last years of a 10 year 
prevention program) + 
comparison with a report on 
prevention activities in 2002 
1986: 
50% regular complianceg 
36.5% irregular complianceh 
13.5% non-compliancei 
1996: 
93.8% regular compliance 
6.2% irregular compliance 
2002: 
> 80% regular compliance 
                                                        
e Minimum recommended number of doses was 13 injections in 12 months 
f Total compliance defined as administration of all scheduled injections within predetermined time frames 
g Regular compliance defined as a minimum of 10-11 BPG injections received per year 
h Irregular compliance defined as 6-9 BPG injections received per year 
i Non-compliance defined as 5 BPG injections received per year 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Pelajo et al., 
2010 [23] 
Paediatric 
Rheumatology 
Brazil, South 
America 
Rio de Janeiro Patients recommended to 
receive monthly BPG 
(n=536) 
Mean age 13 ± 3.9yrs; 53% 
females. 
 
Retrospective observational 
study of patients with a 
diagnosis of ARF from 1985 
to 2005 
  
Non-adherencej detected in 35% (188 out of 
536) patients 
 
Robertson et 
al., 2005 
[15] 
 
 
South African 
Medical 
Journal 
South Africa, 
Africa 
Cape Town  Patients recommended to 
receive monthly BPG or oral 
penicillin (n=8; 7 receiving 
monthly BPG, 1 receiving 
oral penicillin) 
 
Qualitative semi-structured 
interviews with 
patients/guardians; date not 
specified 
 
In 7/8 cases, adherence with all 
recommended BPG was reported 
Bassili et al., 
2000 [24] 
 
 
Eastern 
Mediterranean 
Health Journal 
Egypt, Africa Alexandria Patients receiving secondary 
prophylaxis (n=127; 104 
prescribed 2-weekly BPG, 
14 prescribed 4-weekly BPG 
and 9 prescribed oral 
penicillin) Age 0-15yrs 
 
Retrospective observational 
study of patients over 6-12 
months (patients identified in 
Jan-Apr 1998) 
71.2% of patients compliantk in 2-weekly 
BPG group 
28.6% of patients compliant in 4-weekly 
BPG group 
 
Abdel-
Moula et al., 
1998 [14] 
 
 
Journal of the 
Egyptian 
Public Health 
Association 
 
Egypt, Africa Alexandria Patients receiving secondary 
prophylaxis (n=29; 20 
prescribed monthly BPG, 3 
prescribed 3-weekly BPG, 5 
prescribed 2-weekly BPG 
and 1 prescribed oral 
penicillin) 
Age range 6-16yrs 
 
Prospective case-control study 
with questionnaire regarding 
compliance over one year 
(patients identified in 
scholastic year 1993-1994) 
 
31% of patients not compliantl 
  
                                                        
j Patient classified as non-adherent if they missed or delayed >1 dose of BPG during a 6-month period (interval between appointments) 
k Patient considered compliant if received at least 11 BPG injections in the last 6 months or 22 BPG injections in the last year 
l Patient considered not compliant if received <80% of prescribed BPG injections per year 
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Author, 
Year 
Source Country/ 
Continent 
City/Region/ 
State/Territory 
Prophylaxis regimen/Study 
population 
Study design Summary of findings 
Kassem et 
al., 1995 
[25] 
 
Egyptian Heart 
Journal 
Egypt, 
Africa 
Alexandria Patients recommended to receive 
secondary prophylaxis, 
unspecified regimen (n=86) 
Age range 16-32yrs (mean 
20.8±3.15yrs); 63% females 
Retrospective 
observational study over 
11-20 years (patients 
identified 1972-1980) 
 
Approximately 35% of patients 
uncompliantm 
Kumar et al., 
2002 [26] 
 
 
Indian Heart 
Journal 
India, Asia Ambala, Haryana Patients recommended to receive 
monthly BPG (n=257, 23-134 
patients eligible per year) 
Age 6-20yrs 70.8% 
 
Retrospective 
observational study 
1988-1999 
Mean yearly compliancen: 92%; annual 
variation 82.4-100% 
 
 
 
Kumar et al., 
1997 [27] 
 
 
Indian Heart 
Journal 
India, Asia Ambala, Haryana Patients recommended to receive 
monthly BPG (n=110 in 1995, 
n=17-106 in 1988-1994) 
In 1995, age range 6-50yrs 
(43.7% aged 6-15yrs, 43.7% aged 
16-25yrs); 48.2% male 
 
Retrospective 
observational study 
1988-1995 
1995: 83.6% of patients complianto  
1988-1994: >90% of patients compliant 
 
Lue et al., 
1996 [28] 
Lue et al, 
1994 [13] 
 
Journal of 
Pediatrics 
Taiwan, 
Asia 
Taipei Patients prescribed 3-weekly and 
4-weekly BPG (n=249; 124 
prescribed 3-weekly BPG, 125 
prescribed 4-weekly BPG 
Age range 3-25yrs 
Randomized controlled 
trial 1979-1989 
3-weekly BPG group: 66.9% stay-in 
(complete) compliancep, 15.3% partial 
complianceq, 9.7% dropoutr 
4-weekly BPG group: 73.6% stay-in 
(complete) compliance, 15.2% partial 
compliance, 9.2% dropout 
 
 
  
                                                        
m Definition of uncompliant not provided 
n Compliance defined as percentage of those eligible for secondary prophylaxis who received secondary prophylaxis 
o Missed no more than 1 BPG injection per year 
p Complete compliance defined as  1 BPG injection missed per year 
q Partial compliance defined as 2-3 BPG injections missed per year 
r Dropout defined as  4 BPG injections missed per year 
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Factors associated with adherence 
Ten of the included studies discussed factors associated with adherence to secondary prophylaxis (Table 3). 
Qualitative, semi-structured interviews were conducted in seven of these studies, two of which additionally 
included questionnaires. Multivariate logistic regression was performed in one study[9] and other inferential 
statistical analysis was performed in two studies.[18, 19]
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Table 3: Factors associated with adherence to secondary prophylaxis for ARF and RHD 
Authors Source Location Prophylaxis regimen/Study 
population 
Study design Summary of Findings 
Gasse et al., 
2013 [9] 
 
 
BioMed Central 
Public Health 
Lifou, New 
Caledonia 
 
 
Patients recommended to 
receive 3-weekly BPG 
(n=70) 
Mean age 22.3 ± 11.6yrs 
(43%<16yrs); 63% females. 
Retrospective cohort 
study over 12 months in 
2011 
Multivariate logistic 
regression model 
Factors protective against poor adherence: a household with >5 people 
(odds ratio 0.25, 95% CI 0.08-0.75), a previous medical history of 
symptomatic ARF (odds ratio 0.20, 95% CI 0.04 to 0.98), adequate 
healthcare coverage (odds ratio 0.21, 95% CI 0.06-0.72). 
Stewart et 
al., 2007 
[18] 
 
 
Australian Journal 
of Rural Health 
Katherine, 
Northern 
Territory, 
Australia 
Patients recommended to 
receive monthly BPG (n=59) 
Age <18yrs 32%; 66% 
females. 
Retrospective 
observational study over 
24 months from Sept 
2002 to Sept 2004 
In those who received 50% of prescribed BPG, non-significant trend 
towards improved adherence seen in patients aged <18 years 
(RR=1.26) and those who attended a health clinic more frequently for 
other reasons (RR=1.42). 
Patients with more severe disease less likely to receive monthly BPG 
(RR=0.60). 
Men and women equally likely to receive monthly BPG (RR=1.09). 
Harrington 
et al., 2006 
[10] 
 
 
Medical Journal 
of Australia 
North East 
Arnhem Land, 
Northern 
Territory, 
Australia 
Patients recommended to 
receive monthly BPG, 
relatives and health care 
workers (n=51; 15 patients, 
18 relatives, 18 health care 
workers) 
Patient age range 20-60yrs 
(range of time since 
diagnosis 1-30yrs); female 
n=45, male n=6 
Qualitative semi-
structured interviews 
conducted Apr-Aug 2003 
 
Staff factors promoting uptake: appropriately trained, socially and 
culturally competent staff, an active recall system, staff willingness to 
treat the patient at home. 
Patient factors promoting uptake: an appropriate location for receiving 
injections, belief that the disease is chronic and serious, confidence in 
the health service and receipt of holistic care, family support for and 
belief in the efficacy of treatment. 
Staff factors inhibiting uptake: negative perception of the secondary 
prophylaxis program, conflicting priorities for staff, no effective 
strategy for dealing with absent patients, staff fatigue and frustration 
Patient factors inhibiting uptake: conscientious refusal of treatment, 
inconvenience to the patient, not “belonging” to the health service, lack 
of family support, lack of confidence in the treatment. 
Factors not clearly related to treatment uptake: patient biomedical 
understanding of the disease, taking responsibility for health and 
perception of painfulness of the treatment. 
Eissa et al., 
2005 [19] 
 
 
Australian and 
New Zealand 
Journal of Public 
Health 
Northern 
Territory, 
Australia 
Patients recommended to 
receive 3-4 weekly BPG 
(n=52) 
Male n=15 
Retrospective 
observational study over 
12 months (patients 
identified in Aug 2004) 
Females significantly more likely to receive treatment than males 
(p=0.004). 
Higher adherence rate (median doses 10/year) in moderate or severe 
disease compared with mild disease (median doses 8/year). 
Mincham et 
al., 2003 
[29] 
 
Australian Journal 
of Rural Health 
Kimberley, 
Western 
Australia, 
Australia 
Patients/parents of patients 
recommended to receive 
monthly BPG (n=7) 
Qualitative semi-
structured interviews in 
1998 
Compliance with secondary prophylaxis associated with positive 
patient–staff interactions. 
Living in a remote location was a negative influence. 
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Participants had variable levels of understanding of the disease and 
need for BPG. 
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Authors Source Location Prophylaxis regimen/Study 
population 
Study design Summary of Findings 
Grayson et 
al., 2006 
[11] 
New Zealand 
Medical Journal 
Auckland, 
New Zealand 
Nurses involved with delivery 
of 3-4 weekly BPG (n=9) 
Qualitative semi-
structured interviews; 
date not specified 
Presence of community health workers, a rheumatic fever resource 
nurse and communication from other services used by rheumatic fever 
patients impacted positively on the delivery of secondary prophylaxis. 
Robertson et 
al., 2005 
[15] 
 
 
South African 
Medical Journal 
Cape Town, 
South Africa 
Caregivers of patients (n=8); 
physicians (n=24)  
Qualitative semi-
structured interviews 
with caregivers of 
patients + 24 
physician 
questionnaires; date 
not specified 
There was very poor knowledge of the disease amongst 
patients/guardians, however this was not associated with non-
adherence to secondary prophylaxis. 
Bassili et al., 
2000 [24] 
 
 
Eastern 
Mediterranean 
Health Journal 
Alexandria, 
Egypt 
Caregivers of children and 
children receiving secondary 
prophylaxis (n=127; 104 
prescribed 2-weekly BPG, 14 
prescribed 4-weekly BPG and 9 
prescribed oral penicillin) 
Retrospective chart 
review of compliance 
over 6-12 months 
(patients identified in 
Jan-Apr 1998) + 
questionnaire based 
qualitative interviews 
in Jan-Apr 1998 
Stepwise logistic 
regression 
Non-compliance was more common among children whose parents had 
lower educational and occupational levels, those whose parents had 
only fair to poor knowledge of the disease, those living in semi-urban 
and rural areas, those with health insurance and those whose families 
were not satisfied with the health care provided. 
Kumar et al., 
2002 [26] 
 
 
Indian Heart 
Journal 
Ambala, 
Haryana, India 
Patients recommended to 
receive monthly BPG 
(n=unclear; 40 non-compliant 
patients + an unknown number 
of compliant patients – total 
number of participants in 
associated quantitative study = 
257) 
Qualitative, semi-
structured interviews 
in 1999 
Reasons for non-compliance: fear/dislike of injections, belief that 
injections were no longer required given seemingly good health, lack 
of awareness of the importance of secondary prophylaxis and services 
not available locally. 
Kumar et al., 
1997 [27] 
 
 
Indian Heart 
Journal 
Haryana, India Patients recommended to 
receive monthly BPG (n=110) 
Mean age 18.4 ± 8.6yrs; 48.2% 
male. 
 
Qualitative semi-
structured interviews 
conducted in 1995 
Reasons for non-compliance: private doctors ceasing BPG injections, 
unsupportive family members, a disinterest in BPG injections and long 
distances of travel to health clinics. 
No significant association between non-adherence and low 
socioeconomic background. 
No significant association between non-adherence and level of 
education of parents. 
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Quality assessment 
Use of the quality assessment tool demonstrated the methodological quality of each of the included studies 
(Table 4).
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Table 4: Qualityative assessment 
Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Abdel-
Moula et 
al., 1998 
[14] 
Yes Yes Yes 
 
Yes Yes Yes No No Not relevant Not relevant 
Bassili et 
al., 2000 
[24] 
Yes Yes No Yes Not relevant Yes Yes Yes Not relevant Not relevant 
Eissa et 
al., 2005 
[19] 
Yes Yes No Yes Unknown Yes Yes No Not relevant Not relevant 
Gasse et 
al., 2013 
[9] 
Yes Yes No Yes Yes Yes Yes Yes Not relevant Not relevant 
Grayson et 
al., 2006 
[11] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes No No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Harrington 
et al., 
2006[10] 
Yes Yes Not relevant Not relevant Not relevant No No No Yes Yes 
Kassem et 
al., 1995 
[25] 
Yes No No Unknown Not relevant No No No Not relevant Not relevant 
Kearns et 
al., 2010 
[17] 
Yes Yes Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant No Yes No Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
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Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Kumar et 
al., 2002 
[26] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes Yes  No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Kumar et 
al., 1997 
[27] 
Yes Yes Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes Yes No Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Lue et al., 
1996 [28]; 
Lue et al., 
1994 [13] 
Yes Yes No 
 
Yes Yes Yes Yes No Not relevant Not relevant 
Mincham 
et al., 
2003 [29] 
Yes No Not relevant Not relevant Not relevant Yes No No Yes Yes 
Mincham 
et al., 
2002 [20] 
Yes Yes No Yes Not relevant Yes No No Not relevant Not relevant 
Nordet et 
al., 2008 
[22] 
Yes Yes No Yes Not relevant Yes Yes 
 
No Not relevant Not relevant 
Pelajo et 
al., 2010 
[23] 
Yes Yes No Yes Yes No Yes No Not relevant Not relevant 
Remond et 
al., 2013 
[16] 
Yes Yes No Unknown Not relevant Yes Yes No Not relevant Not relevant 
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Study, 
Year 
Clear 
research 
objectives 
with 
suitable 
data 
collection 
Definition 
of 
adherence 
clear 
Sample size 
calculation 
reported and 
target sample 
size reached 
Recruitment of 
participants 
using probability 
sampling 
Participant 
groups 
comparable 
Outcome 
data complete 
/Response 
rate 
acceptable  
Any 
inferential 
statistical 
analysis 
Multivariate 
analysis of 
factors 
associated 
with 
adherence 
Consideration 
given to 
contextual 
relation of 
findings 
Consideration 
given to 
researchers’ 
influence in 
relation to 
findings 
Robertson 
et al., 
2005[15] 
Yes No Quantitative 
component: No 
Qualitative 
component: not 
relevant 
Quantitative 
component: Yes 
Qualitative 
component: not 
relevant 
Not relevant Yes No No Quantitative 
component: not 
relevant 
Qualitative 
component: Yes 
Quantitative 
component: not 
relevant 
Qualitative 
component: No 
Seckeler et 
al., 2010 
[21] 
Yes Yes No Yes Yes Yes Yes No Not relevant Not relevant 
Stewart et 
al., 2007 
[18] 
Yes Yes No Yes Yes Yes Yes No Not relevant Not relevant 
 
 21 
 
Discussion 
Over the last 20 years, studies addressing adherence to secondary prophylaxis for ARF/RHD have been 
conducted in India, Egypt, South Africa, Brazil, Cuba, the Northern Mariana Islands, Australia, New 
Zealand, New Caledonia and Taiwan. On review of this literature, there was a range of adherence to 
different regimens of BPG prescribed as secondary prophylaxis worldwide. Whilst a small number of 
studies conducted in Cuba, India and New Zealand reported good overall adherence, adherence 
measured in the majority of studies was sub-optimal. An individual range of 0-100% of prescribed 
injections also indicated that despite overall adherence rates, some patients received inadequate BPG 
injections whilst others received appropriate prophylaxis. Adherence to BPG was not evidently better 
or worse amongst minority groups and migrants in developed countries compared with adherence in 
developing countries. Very few studies assessed adherence over time in comparable populations with 
the same definitions, so global trends regarding this could not be established. In the Cuban study, 
adherence improved over time from 50% regular compliance in 1986 to >80% regular compliance in 
2002,[22] whilst Indian studies demonstrated an adherence decline from 100% compliance in 1988 to 
82.4% compliance in 1999.[26, 27] 
 
Factors associated with lower adherence 
In underprivileged settings where ARF and RHD remain prevalent, there are a number of interrelated 
factors associated with low adherence to secondary prophylaxis. Rurality with limited access to health 
care was one important theme in four studies, one involving logistic regression analysis (Bassili et al.) 
and three others including qualitative semi-structured interviews. Bassili et al. reported non-adherence 
to be more common amongst children in semi-urban and rural areas,[24] Mincham et al. found that 
living in a remote location was a negative influence on adherence[29] and two Indian studies identified 
lack of local services and long distances of travel as reasons for non-adherence.[26, 27] It follows that 
for patients living in rural and remote areas with lesser access to health care, adhering to secondary 
prophylaxis regimens may be more difficult. 
 
Negative patient, staff and health service interactions were also reported as contributors to non-
adherence in three studies. Bassili et al.’s logistic regression analysis found non-adherence to be more 
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common among children whose families were not satisfied with the health care provided,[24] and 
qualitative semi-structured interviews performed by Mincham et al. and Harrington et al. in Australia 
highlighted that negative patient-staff interactions, limited confidence in the treatment and a lack of 
sense of “belonging” to the health service could reduce adherence.[10, 29] Mincham et al. and 
Harrington et al.’s studies also discussed staff factors inhibiting uptake, including the transient nature 
of staff in remote settings, a negative perception of the secondary prophylaxis program, conflicting 
health priorities, and no effective strategy for dealing with absent patients leading to staff frustration 
and fatigue.[10, 29] These findings may be most relevant to Australian Indigenous populations and 
other minority groups in developed countries, where a difference in cultural values, attitudes and 
beliefs between the patient/caregiver and health care provider may exist. In Mincham et al.’s study, 
lack of an effective reminder system for due injections additionally led to non-adherence to secondary 
prophylaxis.[29] 
  
Other factors associated with non-adherence included lack of family support (observed in two 
qualitative studies)[10, 27] a disinterest in or conscientious refusal of treatment (discussed in two 
qualitative studies)[10, 27] and inconvenience of the treatment or treatment interference with personal 
priorities (identified in two qualitative studies).[10, 29]  
 
On the field, lack of BPG supply is another known factor leading to lower rates of BPG administration, 
however this was not raised in the studies reviewed. In prospective studies, this is likely because BPG 
supply was ensured for the study population. In retrospective observational studies, it may be that 
supply was assumed to have been adequate by the researchers, and in qualitative interviews and 
questionnaires perhaps the focus was on individual and health service factors, without consideration of 
pharmaceutical supply. 
 
Factors associated with higher adherence 
Factors associated with higher adherence were also identified in the literature reviewed. Positive 
patient, staff and health system interactions promoted adherence in three small qualitative studies in 
Australia and New Zealand. Mincham et al. found that adherence was closely linked with positive 
patient-staff interactions[29] whilst Harrington et al. identified that patient confidence in the health 
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service and receipt of holistic care, as well as family support for and belief in the treatment, were 
important to adherence.[10] The presence of appropriately trained, socially and culturally competent 
staff was discussed by Harrington et al. as a factor associated with higher adherence[10] and supported 
by Grayson et al.’s report that the presence of community health workers and a rheumatic fever 
resource nurse impacted positively on adherence.[11] Harrington et al. additionally found that an 
appropriate location for injections and staff willingness to treat patients at home promoted uptake.[10] 
These study findings may have greater applicability in countries similar to Australia and New Zealand, 
where ARF/RHD is most prevalent amongst migrant and minority groups. In Harrington et al.’s study, 
recall systems for patients with due BPG injections were also associated with higher adherence.[10]  
 
Opportunistic communications may improve adherence to secondary prophylaxis. A qualitative study 
by Grayson et al. found that communication from other services used by rheumatic fever patients 
impacted positively on adherence,[11] and Stewart et al.’s retrospective study involving inferential 
analysis described a non-significant trend towards improved adherence in patients who attended a 
health clinic more frequently for reasons other than secondary prophylaxis.[18] 
 
Patient demographic factors including younger age and greater number of people per household could 
also positively influence adherence to secondary prophylaxis. Stewart et al. found a non-significant 
trend towards improved adherence in patients aged <18 years compared with patients aged ≥18 years 
amongst those who received ≥50% of prescribed BPG.[18] Perhaps this is because parents/caregivers 
are overseeing adherence in younger patients; young adults newly responsible for their own health care 
may have a tendency towards non-adherence. Meanwhile, Gasse et al.’s retrospective study involving 
multivariate logistic regression analysis identified that a household with ≥6 people was protective 
against poor adherence. It is postulated that this may be because older siblings in the household are 
able to assist with health care seeking.[9] 
 
 
Factors with unclear association to adherence 
A number of factors had an unclear association with adherence to secondary prophylaxis. Biomedical 
knowledge of ARF and RHD was poor amongst patients and their families, yet whilst Bassili et al. 
described non-adherence to be more common in patients who’s parents had only a fair to poor 
 24 
knowledge of the disease,[24] Robertson et al. reported no association between knowledge of the 
disease and adherence.[10, 15, 29] Harrington et al. found that an understanding of the chronic and 
serious nature of the disease was more relevant than biomedical knowledge.[10] The fact that indicated 
BPG injections were ceased by patients due to seemingly good health in Kumar et al.’s study also 
suggests that a level of understanding of the disease course is needed.[26] Certainly, delivering 
education was thought to be a worthwhile intervention by many and remains an intuitively key aspect 
of health care.[9, 26, 29] Conflicting results regarding the relationship between patients’ parents’ level 
of education and adherence to secondary prophylaxis were also reported, with Bassili et al. describing 
non-adherence to be more common amongst children whose parents had lower levels of education and 
occupation[24] and Kumar et al. finding no association between parents’ level of education and 
patients’ adherence to secondary prophylaxis.[27] 
 
Certain patient demographic and clinical factors also have an unclear association with secondary 
prophylaxis adherence. Eissa et al. found that service delivery was better for females than males,[19] 
however Stewart et al. found that males and females were equally likely to receive monthly BPG.[18] 
Gasse et al. reported adequate healthcare coverage was protective against poor adherence, [9] yet 
Bassili et al. described non-adherence as more common in children with health insurance compared to 
those without.[24] Eissa et al. also found that adherence was higher among patients with moderate or 
severe disease compared to patients with mild disease.[19] In similar vein, Gasse et al. found that a 
previous medical history of symptomatic ARF was protective against poor adherence.[9] However, in 
Stewart et al.’s study patients with more severe disease were less likely to receive monthly BPG.[18] 
 
Pain and dislike of injections as well as the issue of responsibility for injection delivery are other 
important considerations in adherence. According to one qualitative study, pain associated with 
injections was not necessarily a deterrent to secondary prophylaxis uptake,[10] however in two 
qualitative studies, fear/dislike of injections was given as a reason for non-adherence.[26, 27] 
Harrington et al. and Mincham et al. both commented on the balance of health seeking and health 
delivery responsibility between patients, caregivers and health staff, [10, 29] A common understanding 
of roles and responsibilities in a given community appears important to ensuring BPG administration 
occurs.[10, 29]  This balance may differ in urban compared to rural settings, especially in Australia 
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where historically a more paternalistic approach to rural Indigenous health care delivery has been 
taken.[10] Adherence to secondary prophylaxis for ARF and RHD is evidently a complex and multi-
factorial issue. 
 
 
Strengths and weaknesses 
To the best of our knowledge, this is the first systematic review exploring rates of adherence and 
factors associated with adherence to secondary prophylaxis for ARF and RHD. Our review was 
conducted using PRISMA guidelines to ensure a transparent and complete reporting system. However, 
formal data synthesis with meta-analysis was unable to be performed as authors used different study 
designs and definitions of adherence, and there were differing regimens for secondary prophylaxis 
recommended worldwide. Despite this limitation, our use of a modified validated tool for 
methodological quality assessment allows for the appraisal of included studies.  
 
When examining factors associated with adherence to secondary prophylaxis, it should be taken into 
consideration that the number of studies from different geographical regions is not proportional to the 
prevalence of ARF and RHD in those regions. There were six studies from Oceania (four conducted in 
Australia), two from India, one from Egypt and one from South Africa, whereas India has the highest 
prevalence of ARF/RHD among these locations. Care must be taken when interpreting and applying 
review findings within a local context. However, an overlap in factors pertinent to adherence in the 
different study regions, such as the effect of rurality and access to health services, suggests that some 
findings may be universally relevant. 
 
 
What is the current knowledge gap? 
Knowledge of rates of adherence to secondary prophylaxis for ARF and RHD promotes an accurate 
appreciation of the problem of poor uptake. Further studies reporting rates of adherence worldwide are 
hence warranted, as these data are not available in many countries and may be outdated in others. 
 
Future research may also further explore factors associated with adherence to BPG injections given the 
limited number of studies addressing this worldwide and global variation in population sociocultural 
demographics. An understanding of factors associated with adherence can be used by doctors, nurses, 
 26 
community health workers and policy makers to improve service delivery. Patient self-awareness of 
these factors may also assist in overcoming barriers to receiving secondary prophylaxis. 
 
Can the situation be improved? 
Interventions to improve adherence to secondary prophylaxis that could be adopted by established 
ARF/RHD control programs include ensuring an effective active recall system,[9, 23] involving 
community health workers[30] and delivering education about the disease and its management.[9] It is 
commonly said, “What gets measured gets managed.” Thus, it may be worthwhile to record reasons for 
failure of patients to attend for BPG injections. This could be made part of a specific protocol for when 
secondary prophylaxis is missed, with individual follow-up and troubleshooting by a community health 
worker who has knowledge of local sociocultural and geographic influences. Facilitating a holistic 
approach in service delivery so that patients and their families feel supported and confident in the care 
received is vital.[10, 24, 27] It should be noted that these interventions can only be achieved with 
adequate and sustained financial support and staff resources.[19] 
 
 
Conclusion 
Current literature provides some insight into levels of adherence and factors associated with adherence 
to secondary prophylaxis for ARF and RHD. However, further studies are warranted to develop a 
better understanding of current adherence rates and factors associated with adherence worldwide. 
Improved delivery of secondary prophylaxis is necessary to ensure best health outcomes for affected 
pediatric and young adult populations. Interventions to achieve this should target patient demographic, 
clinical, sociocultural and health service delivery factors with known association to adherence, and 
may include implementation of an active recall system, provision of holistic care, involvement of 
community health workers and delivery of ARF/RHD health education.  
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